22:43 , May 28, 2019 |  BC Extra  |  Company News

Management tracks: Atara names Novartis’ Touchon as CEO; plus Intellia, Arch Oncology

Atara Biotherapeutics Inc. (NASDAQ:ATRA) hired Pascal Touchon as president and CEO, effective June 24. He was global head cell & gene at Novartis AG (NYSE:NVS; SIX:NOVN), where he was responsible for the global launch of...
12:02 , Mar 25, 2019 |  BC Extra  |  Financial News

Arch Oncology raises $50M series B to develop anti-CD47 mAb

Backed by new investor Lightchain, Arch Oncology raised $50 million in a series B round to enable the company to advance its anti-CD47 mAb, AO-176, which is in a Phase I trial to treat solid...
07:00 , Aug 25, 2016 |  BC Innovations  |  Targets & Mechanisms

Forty Seven and counting

With companies lining up to block CD47 for cancer, the cell surface protein is emerging as one of the top new targets in oncology. But the list of suitors could be about to get a...
07:00 , Aug 22, 2016 |  BioCentury  |  Finance

Tioma's broad basket

Tioma Therapeutics Inc. will avoid putting its eggs in one basket and use last week's tranched $86 million series A round to launch a broad clinical program targeting CD47 . President and CEO John Donovan...
07:00 , Aug 22, 2016 |  BC Week In Review  |  Financial News

Tioma completes venture financing

Tioma Therapeutics Inc. , Brisbane, Calif.   Business: Cancer   Date completed: 2016-08-16   Type: Venture financing   Raised: $86 million   Investors: RiverVest Venture Partners; Novo Ventures; Roche Venture Fund; SR One  ...
07:00 , Aug 16, 2016 |  BC Extra  |  Top Story

Tioma raises $86M for anti-CD47 antibodies

Immuno-oncology play Tioma Therapeutics Inc. (Brisbane, Calif.) raised $86 million in a series A round co-led by RiverVest Venture Partners, Novo Ventures, Roche Venture Fund and SR One. Tioma also named John Donovan president and...